Biogen (BIIB) Gains from Investment Securities (2009 - 2026)

Biogen's Gains from Investment Securities history runs 18 years deep, the most recent figure standing at $20.5 million for Q1 2026.

• In Q1 2026, Gains from Investment Securities rose 150.12% year-over-year to $20.5 million; the TTM figure through Mar 2026 stood at $53.7 million (up 120.24% YoY), while the FY2025 annual figure was -$19.3 million, up 87.91% from the prior year.
• Gains from Investment Securities was $20.5 million for Q1 2026 at Biogen, up from $14.4 million in the prior quarter.
• In the past five years, Gains from Investment Securities ranged from a high of $503.7 million in Q3 2022 to a low of -$513.3 million in Q4 2022.
• Historically, Gains from Investment Securities has averaged -$6.5 million across 5 years, with a median of $13.2 million in 2025.
• The sharpest annual moves came in 2023 and 2024: Gains from Investment Securities jumped 1543.01% in 2023, then slumped 2582.0% in 2024.
• A 5-year view of Gains from Investment Securities shows it stood at -$513.3 million in 2022, then surged by 101.95% to $10.0 million in 2023, then plunged by 2582.0% to -$248.2 million in 2024, then surged by 105.8% to $14.4 million in 2025, then jumped by 42.36% to $20.5 million in 2026.
• The last three Gains from Investment Securities figures came in at $20.5 million (Q1 2026), $14.4 million (Q4 2025), and $5.6 million (Q3 2025), per Business Quant data.